LOGIN  |  REGISTER
Recursion
Assertio

BioLife Solutions to Report Fourth Quarter and Full Year 2024 Financial Results and Business Update on March 3, 2025

February 20, 2025 | Last Trade: US$23.29 0.93 4.16

BOTHELL, Wash., Feb. 20, 2025 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer and supplier of bioproduction products and services for the cell and gene therapy ("CGT") market, today announced the 2024 fourth quarter and full year financial results will be released on March 3, 2025 pre-market. The Company will host a conference call and live webcast at 8:00am ET (5:00am PT) that day. Management will provide an overview of the Company's financial results and give a general business update.

To access the webcast, log onto the Investor Relations page of the BioLife Solutions website at https://www.biolifesolutions.com/earnings. In addition, the conference call will be accessible by dialing toll-free 1-833-630-0431 or 1-412-317-1808 for international callers.  A webcast replay will be available approximately two hours after the call and will be archived on https://investors.biolifesolutions.com for 90 days.

About BioLife Solutions

BioLife Solutions is a leading developer and supplier of bioproduction products and services for the cell and gene therapy (CGT) and broader biopharma markets. Our expertise facilitates the commercialization of new therapies by supplying solutions that maintain the health and function of biologic materials during collection, development, storage, and distribution. For more information, please visit www.biolifesolutions.com or follow BioLife on LinkedIn and X.

Media & Investor Relations

At the Company
Troy Wichterman
Chief Financial Officer
(425) 402-1400
This email address is being protected from spambots. You need JavaScript enabled to view it.

Investors
Alliance Advisors IR
Jody Cain
(310) 691-7100
This email address is being protected from spambots. You need JavaScript enabled to view it.

Assertio

Stock Quote

Featured Stock

ClearPoint Neuro

ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...

CLICK TO LEARN MORE

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page